2024 Safety Communications
Listing of Medical Device 2024 Safety Communications
Italiano
Listing of Medical Device 2024 Safety Communications
This device has significantly changed since FDA authorization, and the safety and effectiveness of the modified device has not been established.
En combinaison avec la gemcitabine dans le traitement du cancer du pancréas avancé (localement avancé, non résécable ou métastatique) qui a déjà été traité.
Herpes simplex virus-2 serological tests can produce false reactive results especially if a person has a low risk of infection or if test results are near the test’s cut-off.
Hospira, Inc., a Pfizer company, is voluntarily recalling the lots listed in the table below of 4.2% Sodium Bicarbonate Injection, USP ABBOJECT® Glass Syringe, 5 mEq/10 mL; 8.4% Sodium Bicarbonate Injection, USP Lifeshield® ABBOJECT® Glass Syringe, 50 mEq/50 mL; and Atropine Sulfate Injection, USP L
Hospira, Inc., a Pfizer company, is voluntarily recalling one lot of Bleomycin for Injection, USP 15 units Single Dose ONCO-TAIN™ Glass Fliptop Vial, lot BL12206A, to the user level. The recall was initiated due to a confirmed customer report for the presence of glass particulate within a single via
Insight Pharmaceuticals, a Prestige Consumer Healthcare Inc. company (“Insight”), is voluntarily recalling one lot of Americaine® 20% Benzocaine Topical Anesthetic Spray to the consumer level. While benzene is not an ingredient in any Americaine® 20% Benzocaine Topical Anesthetic Spray products, a r
ResMed (NYSE: RMD, ASX: RMD) is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about potential magnetic interference when magnets are near certain implants and medical devices in the body. This voluntary field correction does not require a
granulomatose éosinophilique avec polyangéite
80.211.154.110